Clinical Trials Directory

Trials / Unknown

UnknownNCT05067959

Covid-19 Vaccine Responses in Patients With Inflammatory Bowel Diseases

Status
Unknown
Phase
Study type
Observational
Enrollment
284 (actual)
Sponsor
Rabin Medical Center · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

The 2019-coronavirus disease (COVID-19), caused by SARS-CoV-2, was identified as the source of pneumonia cases in Wuhan city in China. It rapidly spread worldwide and was declared by WHO as a pandemic. COVID-19 vaccines are expected to be the breakthrough in controlling the pandemic. However, studies performed only in healthy adults, and specifically excluded patients who were under immunomodulatory/biologic therapy, thus excluding patients with chronic inflammatory diseases (IBD). In this study we wish to understand vaccine efficacy and immunological response in IBD patients.

Detailed description

Overall Aims: 1. To assess the immune response to COVID-19 vaccination in patients with IBD. 2. Comparing the short and long term immune response to vaccination among subgroups receiving different therapies. 3. To evaluate the different variables affecting immunity of these patients. 4. To assess adverse reactions to COVID-19 vaccines and IBD related complications. Specifically: 1. To assess serologic response to COVID-19 vaccine(s) in patients with IBD treated with anti-TNF agents (+/- immunomodulators) compared to 1. Healthy controls 2. Patients with IBD not treated with anti-TNF (+/- immunomodulators) 2. To characterize serologic response: seroconversion, seroprotection and persistence of COVID-19 vaccine(s) in patients with IBD 3. To identify factors associated with serologic response 4. Side effects to vaccines 5. IBD exacerbation compared to activity at baseline 6. Symptomatic COVID-19

Conditions

Interventions

TypeNameDescription
BIOLOGICALCovid-19 vaccineblood tests and questioners before 1st vaccine, 3 weeks before 2nd vaccine, 4 weeks after 2nd vaccine, 6 months after 1st vaccine, and 12 months after 2nd vaccine

Timeline

Start date
2020-12-28
Primary completion
2021-12-01
Completion
2022-03-01
First posted
2021-10-05
Last updated
2021-10-05

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT05067959. Inclusion in this directory is not an endorsement.